A virus that shows promise as a means of vaccine delivery of HIV-1 antigens could be altered to become effective in a larger portion of the population according to research published online by Nature this week.
Adenovirus serotype 5 (Ad5) vectors carrying HIV-1 antigens have been shown to generate high immune responses in preclinical studies and are therefore being developed as candidate AIDS vaccines. A problem facing researchers is that a large majority of the human population has pre-existing Ad5-specific neutralizing antibodies that could reduce the effectiveness of this particular vaccine vector.
Knowing that many Ad5-specific antibodies target the outer capsid hexon protein, Dan Barouch and colleagues swapped the surface loops - hypervariable regions - with the corresponding hypervariable regions from another adenovirus with lower pre-existing immunity in humans.
They found that these chimaeric carriers were stable and effectively evaded pre-existing anti-Ad5 immunity in both mice and rhesus monkeys. Furthermore, a high immune response was generated against the encoded vaccine antigen: the Gag protein from simian immunodeficiency virus. These engineered vaccine vectors could provide a major advance for the fields of vaccination and gene therapy.
Dan H. Barouch (Harvard Medical School, Boston, MA, USA)
Abstract available online.
(C) Nature press release.
Message posted by: Trevor M. D'Souza
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking